“A substantial amount of confidential data — including commercial secrets — is currently consolidated within a unified information framework. Therefore, ensuring an adequate level of trust in the new procedures is critically important for the EEC. One of the subsequent stages in developing the regulatory environment may involve establishing an analogue of the European Medicines Agency (EMA), which would assume responsibility for coordinating scientific evaluation and marketing authorization processes,” Kharitonov emphasized.